Massachusetts Cannabis Study Finds Consumer Concerns on Potency, Tax Spending
New research shows Bay State cannabis consumers prioritize product potency accuracy and transparency in how the state spends marijuana tax revenue.

A breathtaking view of Boston's skyline with the Massachusetts State House at sunset, showcasing its iconic golden dome.
Study Highlights Consumer Trust Gaps
Massachusetts cannabis consumers expressed skepticism about potency labeling accuracy and state tax spending transparency, according to the WGBH study released August 10. The research surveyed adult-use consumers across the state during the second quarter of 2026.
Potency labeling emerged as a top concern. Consumers said they're uncertain whether THC percentages listed on product packaging accurately reflect tested levels, particularly for flower and concentrates.
Tax Revenue Allocation Under Scrutiny
Respondents questioned how Massachusetts directs cannabis tax dollars, with many unaware of current allocation formulas. The state's cannabis excise tax stands at 10.75 percent, with additional local option taxes up to 3 percent and the standard 6.25 percent sales tax.
Since 2018, Massachusetts has collected over $1.2 billion in cannabis tax revenue. State law directs a portion to the Cannabis Control Commission for regulatory costs, with remaining funds flowing to the general fund and designated programs including public health initiatives and municipalities hosting dispensaries.
Regulatory Framework Context
The Cannabis Control Commission oversees mandatory third-party testing for all products, including potency verification. Licensed testing facilities must follow standardized protocols for cannabinoid analysis, but the study suggests consumer confidence in these systems remains uneven.
Massachusetts regulations require dispensaries to display potency information on all product labels. The CCC can issue violations for mislabeling or inaccurate test results. For complete regulatory background, see the CannIntel topic hub on Massachusetts Cannabis Program.
Industry Response Implications
The findings may pressure operators to enhance transparency around testing protocols and lab selection. Several Massachusetts MSOs have already implemented QR-code systems linking to full certificates of analysis, though adoption varies widely across the state's 240-plus active dispensaries.
Consumer education campaigns around tax allocation could become a priority for industry groups and the CCC. Trade associations have historically focused messaging on product safety and responsible use rather than fiscal policy.
What Comes Next
The CCC's next quarterly meeting is scheduled for September 2026. Tax revenue allocation debates typically surface during the state budget cycle, which begins in January. We'll be watching for legislative proposals around dedicated cannabis tax spending in the 2027 session.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Frequently asked questions
How much cannabis tax revenue has Massachusetts collected?
Massachusetts has collected more than $1.2 billion in cannabis tax revenue since adult-use sales began in November 2018. The state imposes a 10.75 percent excise tax, plus optional local taxes up to 3 percent and the standard 6.25 percent sales tax.
What are Massachusetts consumers concerned about regarding cannabis potency?
Consumers expressed skepticism about whether THC percentages on product labels accurately reflect third-party test results, particularly for flower and concentrates. The study found uneven confidence in the state's mandatory testing protocols.
How does Massachusetts allocate cannabis tax revenue?
State law directs cannabis tax revenue first to the Cannabis Control Commission for regulatory costs. Remaining funds flow to the general fund and designated programs including public health initiatives and municipalities that host dispensaries.
Who oversees cannabis potency testing in Massachusetts?
The Cannabis Control Commission oversees mandatory third-party testing for all cannabis products. Licensed testing facilities must follow standardized protocols for cannabinoid analysis, and the CCC can issue violations for mislabeling or inaccurate results.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

MMJ Challenges CMS Administrator Oz Over Hemp Cannabinoid Endorsement
Medical marijuana operator disputes federal 'no product' stance after CMS head endorses unvalidated hemp-derived cannabinoid line.

Federal Judge Denies Request to Block Texas Hemp Ban
A U.S. district court rejected industry arguments for a temporary restraining order, leaving the state's consumable hemp prohibition in effect.

Georgia regulators tour Macon cultivation site as patient enrollment climbs
State cannabis commission inspects production facility amid rising demand for medical marijuana access.
More from the newsroom

New York CBD Stores Face Dispensary Squeeze as Adult-Use Expands
Legacy hemp retailers pivot to wellness, education, and niche products as licensed cannabis shops multiply statewide.

Cannabis Retailers Shift From Risky Bet to Mainstay in Commercial Leasing
Landlords and brokers report surging demand for dispensary tenants as retail cannabis proves durable across market cycles.

Michigan Retailer Closes Five Dispensaries Citing New Tax Burden
A Michigan cannabis operator is shuttering five locations as the state's revised tax structure squeezes multi-location retailers.